Multiple studies on exosomes, data from the IMvigor 210 trial of atezolizumab (TECENTRIQ), and research on prehabilitation for cystectomy were among the highlights in bladder cancer from the 2016 AUA annual meeting.
Other products discussed in this roundup include a plasma vaporization device, a laser fiber safety device, and more.
Other basic science research pearls include preliminary evidence from a porcine model suggesting botulinum toxin type A facilitates ureteral stone passage and the identification of two different microdeletions in the NELL1 gene on chromosome 11 in men with Peyronie's disease.
A recently released guideline on diagnosis and treatment of nonmuscle-invasive bladder cancer from the AUA and the Society of Urologic Oncology provides practitioners with a risk-stratified clinical framework to aid treatment decisions and surveillance strategies, said Sam S. Chang, MD, MBA.
Urologist Peter Black, MD, discusses the recent FDA approval of atezolizumab (TECENTRIQ) for the most common form of bladder cancer as well as a complementary diagnostic test.
A recent human study sought to replicate previous success seen in animal models of reperfusion injury, reports Urology Times SUO internship program member Katie Murray, DO.
Urology Times SUO internship program member Ryan Hutchinson, MD, reports on a presentation on plasmacytoid urothelial carcinoma and adenocarcinoma.
A novel oral TRT agent, bladder control system, and localized prostate cancer agent are among other treatments in the pipeline discussed in this round-up.
Also look for coverage of products in the pipeline for bladder pain syndrome/interstitial cystitis, prostate cancer, and male infertility.
Peter C. Black, MD, discusses the current state of immune checkpoint inhibition for bladder cancer in this article from Urology Times SUO internship program member William Parker, MD.